Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial

MLA

Yee, Douglas, et al. “Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.” JAMA Oncology, vol. 6, no. 9, Sept. 2020, pp. 1355–62. EBSCOhost, https://doi.org/10.1001/jamaoncol.2020.2535.

APA

Yee, D., DeMichele, A. M., Yau, C., Isaacs, C., Symmans, W. F., Albain, K. S., Chen, Y.-Y., Krings, G., Wei, S., Harada, S., Datnow, B., Fadare, O., Klein, M., Pambuccian, S., Chen, B., Adamson, K., Sams, S., Mhawech-Fauceglia, P., Magliocco, A., & Feldman, M. (2020). Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncology, 6(9), 1355–1362. https://doi.org/10.1001/jamaoncol.2020.2535

Chicago

Yee, Douglas, Angela M. DeMichele, Christina Yau, Claudine Isaacs, W. Fraser Symmans, Kathy S. Albain, Yunn-Yi Chen, et al. 2020. “Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.” JAMA Oncology 6 (9): 1355–62. doi:10.1001/jamaoncol.2020.2535.